Gastroesophageal Reflux Clinical Trial
Official title:
Analysis the Related Factors of Bariatric Surgery on Gastroesophageal Reflux Disease and Its Prevention and Treatment: a Prospective, Multicenter and Randomized Controlled Study
Obesity and related metabolic diseases have become a chronic disease that is a threat to
human health. Bariatric surgery can effectively and long-term reduce excess body weight and
relieve related metabolic diseases, including type 2 diabetes. Laparoscopic gastric bypass
surgery and laparoscopic sleeve gastrectomy are commonly used in bariatric surgery.
Laparoscopic sleeve gastrectomy due to simple operation, good weight loss, and metabolic
disease control effect, which is more widely used. However, there are several studies that
show an increased chance of gastroesophageal reflux disease after laparoscopic sleeve
gastrectomy. Long-term gastroesophageal reflux may lead to Barrett's esophagus or esophageal
cancer. Nowadays, the cause of gastroesophageal reflux disease after sleeve gastrectomy is
not clear and precautionary measures are not precise.
In this study, prospective randomized controlled trials were conducted to explore the
possible causes of gastroesophageal reflux after sleeve gastrectomy and to explore ways to
prevent gastroesophageal reflux disease after sleeve gastrectomy.
With the social development and changes in the lifestyle, the incidence of obesity and type
2diabetes is rapidly increasing. In 2010, the global incidence of type 2 diabetes was 8.3% in
adults, 11.6% in China and 50.1% in China. In overweight and obese people, the prevalence of
type 2 diabetes also increased significantly, and the prevalence of type 2diabetes in those
people with BMI> 30 reached 18.5-23%. Diabetes-induced cardiovascular and cerebrovascular
diseases, renal insufficiency and other complications, seriously affecting the quality of
life of the patients, endangering the safety of life, the treatment of type 2 diabetes and
related complications to public health expenditure has brought tremendous pressure.
Traditional medical methods are difficult to achieve long-term and effective control of type
2 diabetes. Surgery has been shown to achieve 75-95% long-term relief of obesity in patients.
Roux-en-Y gastric bypass (Roux-en-Y gastric bypass, RYGB) and laparoscopic sleeve gastrectomy
are most commonly used. Among them, laparoscopic sleeve gastrectomy is relatively simple, low
incidence of complications, lower operating costs, and gradually become the most important
surgical methods of weight loss and metabolic disease surgery. Numerous clinical studies are
shown that sleeve gastrectomy in patients with type 2 diabetes has the same therapeutic
effect as gastric bypass with a complete remission rate of 70-90% for T2DM.
For the choice of surgical approach, numerous studies have shown that BMI ≧ 45, the general
choice of gastric bypass surgery, BMI <45, participants can choose sleeve gastrectomy. The
remission rate for T2DM, sleeve gastrectomy has a good result for young patients with shorter
duration. In China, the BMI less than 45 is majorities.
According to the previous survey in 2012, the newly diagnosed diabetes patients in China
constituted more than half of all diabetic patients. Since laparoscopic sleeve gastrectomy is
relatively simple, so sleeve gastrectomy is easier to popularize in China and has wide
application prospect.
As an invasive treatment, laparoscopic sleeve gastrectomy also presents opportunities of
surgery-related complications, including gastric leak (0.5-1%), stenosis (0.1-0.5%), bleeding
(about 0.5%), and gastroesophageal reflux disease (GERD). Gastroesophageal reflux disease is
a most common upper gastrointestinal disease, numerous clinical studies shown that the
incidence of GERD in western populations are 10-20%, while obese people are around 37-72%, if
abdominal fat accumulation more obvious, the incidence of GERD will become higher. In China,
there is still no relevant data. Gastric bypass surgery has a clear effect on the treatment
of GERD, and the relationship between sleeve gastrectomy and GERD is still controversial.
Some studies have shown that sleeve gastrectomy did not increase the incidence of
postoperative GERD, while another study showed that the incidence of GERD after sleeve
gastrectomy increased significantly. In addition, no studies have revealed the reasons for
the occurrence of GERD after sleeve gastrectomy and no study showed how to prevent the
occurrence of GERD after sleeve gastrectomy.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05561179 -
Hyaluronic Acid in Patients With Gastroesophageal Reflux Disease
|
N/A | |
Withdrawn |
NCT02213887 -
Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications
|
Phase 4 | |
Completed |
NCT01946971 -
Lansoprazole in Preterm Infants With Gastroesophageal Reflux (GER)
|
Phase 1/Phase 2 | |
Recruiting |
NCT01825473 -
Study of Erythromycin in GER-Associated Apnea of the Newborn
|
N/A | |
Completed |
NCT00614536 -
Study of Changes in Reflux Symptoms and Reflux Finding Score According to Rabeprazole Treatment Period
|
Phase 4 | |
Completed |
NCT00373997 -
Esophageal and Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux
|
Phase 4 | |
Completed |
NCT00284908 -
Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00365300 -
Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)
|
Phase 3 | |
Completed |
NCT01167543 -
Relationship and Pathophysiology of Gastroesophageal Reflux and Dental/Periodontal Disease
|
N/A | |
Completed |
NCT00215787 -
Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease
|
N/A | |
Completed |
NCT00291746 -
Validation of RDQ Questionnaire
|
Phase 4 | |
Completed |
NCT00141960 -
Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease
|
Phase 2/Phase 3 | |
Completed |
NCT00567021 -
German PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-Symptoms
|
N/A | |
Completed |
NCT00226044 -
Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants.
|
Phase 3 | |
Completed |
NCT00181805 -
Natural History of Gastroesophageal Reflux (GER) in Children and Adolescents
|
||
Completed |
NCT01048840 -
Natural History of Gastroesophageal Reflux (GER) in Children < 12 Years of Age
|
||
Terminated |
NCT01281553 -
A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux Disease
|
Phase 4 | |
Completed |
NCT05486169 -
Gastroesophageal Reflux Disease After Laparoscopic Sleeve Gastrectomy
|
N/A | |
Completed |
NCT04034017 -
Gastroesophageal Reflux Disease Among College Students
|
||
Terminated |
NCT03226054 -
Determining Risk Factors for Successful PPI Weaning
|
N/A |